Ketolides: A new class of antibacterial agents for treatment of community-acquired respiratory tract infections in a primary care setting

Mayo Clinic Proceedings

Volumn 78, Issue 9, 2003, Pages 1113-1124

  Clark, Jeffrey Paul ^a,c   Langston, Edward ^b  

^a Educators Mutual Ins Association   (United States)

^b American Health Network   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; KETOLIDE; RIBOSOME RNA; TELITHROMYCIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; CROSS RESISTANCE; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HAEMOPHILUS INFLUENZAE; HEADACHE; HIGH RISK POPULATION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; NAUSEA; PRIMARY MEDICAL CARE; PROTEIN BINDING; RESPIRATORY TRACT INFECTION; REVIEW; STREPTOCOCCUS PNEUMONIAE; TREATMENT PLANNING; VERTIGO; VOMITING;

EID: 0042358739     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/78.9.1113     Document Type: Review

References (91)

1. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ, Infectious Diseases Society of America. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis. 2000;31:347-382.
2. American Academy of Family Physicians. 1999 FACTS about family practice: table 18: number of office visits (in thousands) to selected specialties ranked by 20 most frequent principal diagnoses by visits to family physicians: United States, 1997.
3. Birnbaum HG, Morley M, Greenberg PE, Cifaldi M, Colice GL. Economic burden of pneumonia in an employed population. Arch Intern Med. 2001;161:2725-2731.
4. Neuzil KM, Hohlbein C, Zhu Y. Illness among schoolchildren during influenza season: effect on school absenteeism, parental absenteeism from work, and secondary illness in families. Arch Pediatr Adolesc Med. 2002;156:986-991.
5. Ball P. Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest. 1995;108(2, suppl):43S-52S.
6. Fang GD, Fine M, Orloff J, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy: a prospective multicenter study of 359 cases. Medicine (Baltimore). 1990;69:307-316.
7. Goffried MH. Epidemiology of clinically diagnosed community-acquired pneumonia in the primary care setting: results from the 1999-2000 Respiratory Surveillance Program. Am J Med. 2001; 111(suppl 9A):25S-29S.
8. Gwaltney JM Jr. Acute community-acquired sinusitis. Clin Infect Dis. 1996;23:1209-1223.
9. Incaudo GA, Wooding LG. Diagnosis and treatment of acute and subacute sinusitis in children and adults. Clin Rev Allergy Immunol. 1998;16:157-204.
10. Isada CM. Pro: antibiotics for chronic bronchitis with exacerbations. Semin Respir Infect. 1993;8:243-253.
11. Mandell LA. Community-acquired pneumonia: etiology, epidemiology, and treatment. Chest. 1995;108(2, suppl):35S-42S.
12. Tanz RR, Shulman ST. Diagnosis and treatment of group A streptococcal pharyngitis. Semin Pediatr Infect Dis. 1995;6:69-78.
13. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med. 1995;333:1618-1624.
14. Gwaltney JM. Sinusitis. In: Mandell GL, Douglas RG Jr, Bennett JE, eds. Principles and Practice of Infectious Diseases. 3rd ed. New York, NY: Churchill Livingstone; 1990:493-498.
15. Hammerschlag MR. Community-acquired pneumonia due to atypical organisms in adults: diagnosis and treatment. Infect Dis Clin Pract. 1999;8:232-240.
16. Felmingham D, Grüneberg RN. The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. J Antimicrob Chemother. 2000;45:191-203.
17. Doem GV, Pfaller MA, Kugler K, Freeman J, Jones RN. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America: 1997 results from the SENTRY Antimicrobial Surveillance Program. Clin Infect Dis. 1998;27:764-770.
18. Hoban DJ, Doern GV, Fluit AC, Roussel-Delvallez M, Jones RN. Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moroxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis. 2001;32(suppl 2):S81-S93.
19. Chen DK, McGeer A, de Azavedo JC, Low DE, Canadian Bacterial Surveillance Network. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. N Engl J Med. 1999; 341:233-239.
20. PROTEKT Resistance Surveillance Web site. Available at: www.protekt.org. Accessibility verified July 9, 2003.
21. Stratton CW, Barry A, Yee YC. In vitro activity of telithromycin against clinical isolates of Streptococcus pneumoniae collected from 214 medical centers across the United States during the winter of 2000/2001 [abstract]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, Ill; September 22-25, 2001:190. Abstract E-1018.
22. Aldridge KE, Brown SD, Farrell DJ. Penicillin and macrolide resistant Streptococcus pneumoniae and the in vitro activity of telithromycin across the United States in 2000/2001 [abstract]. In: Program and abstracts of the 40th Annual Meeting of the Infectious Diseases Society of America; Chicago, Ill; October 24-27, 2002. Abstract 37.
23. Feikin DR, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health. 2000;90:223-229.
24. Garau J, Lonks JR, Gomez L, Xercavins M, Medeiros AA. Failure of macrolide therapy in patients with bacteremia due to macrolide resistant streptococcus pneumonia. In: Program and abstracts of the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones; Seville, Spain; January 26-28, 2000. Abstract 7.09.
25. Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis. 2002;35:556-564.
26. Blondeau JM, DeCarolis E, Metzler KL, Hansen GT. The macrolides. Expert Opin Investig Drugs. 2002;11:189-215.
27. Kim BN, Bae LG, Kim MN, et al. Risk factors for penicillin resistance and mortality in Korean adults with Streptococcus pneumoniae bacteremia. Eur J Clin Microbiol Infect Dis. 2002;21:35-42.
28. Gold HS, Moellering RC Jr. Antimicrobial-drug resistance. N Engl J Med. 1996;335:1445-1453.
29. Champney WS, Tober CL. Inhibition of translation and 50S ribosomal subunit formation in Staphylococcus aureus cells by 11 different ketolide antibiotics. Curr Microbiol. 1998;37:418-425.
30. Douthwaite S, Mauvais P, Hansen LH. The C-11/12 Carbamate side chain of the ketolide antimicrobial telithromycin (HMR-3647) enhances binding to both MLS-sensitive and -resistant ribosomes [abstract]. In: Program and abstracts of the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones; Seville, Spain; January 26-28, 2000. Abstract 2.01.
31. Hansen LH, Mauvais P, Douthwaite S. The macrolide-ketolide antibiotic binding site is formed by structures in domains II and V of 23S ribosomal RNA. Mol Microbiol. 1999;31:623-631.
32. Poehlsgaard J, Douthwaite S. The macrolide binding site on the bacterial ribosome. Curr Drug Targets Infect Disord. 2002;2:67-78.
33. Mauvais P, Bonnefoy A. Lack of in vitro MLSB resistance induction by the ketolide telithromycin (HMR 3647): role of the 3-keto group [abstract]. In: Program and Abstracts of the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones; Seville, Spain; January 26-28, 2000. Abstract 2.10.
34. Davies TA, Dewasse BE, Jacobs MR, Appelbaum PC. In vitro development of resistance to telithromycin (HMR 3647), four macrolides, clindamycin, and pristinamycin in Streptococcus pneumoniae. Antimicrob Agents Chemother. 2000;44:414-417.
35. Muller-Serieys C, Soler P, Cantalloube C, et al. Bronchopulmonary disposition of the ketolide telithromycin (HMR 3647). Antimicrob Agents Chemother. 2001;45:3104-3108.
36. Muller-Serieys C, Cantalloube C, Soler P, Gia HP, Brunner F. HMR 3647 achieves high and sustained concentrations in bronchopulmonary tissues [abstract] J Antimicrob Chemother. 1999; 44(suppl A):57. Abstract P78.
37. Leclercq R, Courvalin P. Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification [published correction appears in Antimicrob Agents Chemother. 1991;35:2165]. Antimicrob Agents Chemother. 1991;35:1267-1272.
38. Bonnefoy A, Girard AM, Agouridas C, Chantot JF. Ketolides lack inducibility properties of MLS(B) resistance phenotype. J Antimicrob Chemother. 1997;40:85-90.
39. Agouridas C, Bonnefoy A, Chantot JF. In vivo antibacterial activity of HMR 3647, a new ketolide highly active against respiratory pathogens [abstract]. In: Program and abstracts of the 4th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides, and Oxazolidinones; Barcelona, Spain; January 21-23, 1998. Abstract 1.11.
40. Hoban DJ, Wierzbowski AK, Nichol K, Zhanel GG. Macrolide-resistant Streptococcus pneumoniae in Canada during 1998-1999: prevalence of mef(A) and erm(B) and susceptibilities to ketolides. Antimicrob Agents Chemother. 2001;45:2147-2150.
41. Milatovic D, Verhoef J, Fluit AC. Prevalence and genotypes of macrolide resistant Streptococcus pneumoniae and β-hemolytic streptococci in The Netherlands, Denmark and Luxemburg [abstract]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; Toronto, Ontario; September 17-20, 2000:65. Abstract 140.
42. Morosini MI, Canton R, Loza E, et al, Spanish Collaborative Group. Distribution of erythromycin resistant determinants in Spanish Streptococcus pneumoniae isolates and comparative activity of telithromycin [abstract]. Available at: www.asmusa.org/memonly/abstracts/AbstractView.asp?AbstractID=33901. Accessibility verified July 17, 2003.
43. Hamilton-Miller JM, Shah S. Comparative in-vitro activity of ketolide HMR 3647 and four macrolides against gram-positive cocci of known erythromycin susceptibility status. J Antimicrob Chemother. 1998;41:649-653.
44. Nagai K, Hoellman D, Davies T, Jacobs M, Appelbaum P. Activity of telithromycin against 26 quinolone-resistant pneumococci with known quinolone-resistance mechanisms. Clin Microbiol Infect. 2001;7:703-705.
45. Kitzis MD, Goldstein FW, Bismuth R, Miegi M, Acar JF. Comparative in vitro activity of HMR 3647, a new ketolide antibiotic, against S. aureus (SA) and coagulase negative staphylocci (CNS) [abstract]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; Toronto, Ontario; September 28-October 1, 1997:165.
46. Canu A, Malbruny B, Coquemont M, Davies TA, Appelbaum PC, Leclercq R. Diversity of mutations in L22, L4 ribosomal proteins and 23s ribosomal RNA in pneumococcal mutants resistant to macrolides, telithromycin, and clindamycin selected in vitro [abstract]. Available at: www.asmusa.org/memonly/abstracts/AbstractView.asp?AbstractID=33698. Accessibility verified July 17, 2003.
47. Tait-Kamradt A, Davies T, Cronan M, Jacobs MR, Appelbaum PC, Sutcliffe J. Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob Agents Chemother. 2000;44:2118-2125.
48. Felmingham D. Microbiological profile of telithromycin, the first ketolide antimicrobial. Clin Microbiol Infect. 2001;7(suppl 3):2-10.
49. Dubois J, St-Pierre C. In vitro activity of telithromycin, macrolides and quinolones against respiratory tract pathogens [abstract]. Available at: www.asmusa.org/memonly/abstracts/AbstractView.asp?AbstractlD=34125. Accessibilitiy verified July 17, 2003.
50. Barry AL, Fuchs PC, Brown SD. In vitro activities of the ketolide HMR 3647 against recent gram-positive clinical isolates and Haemophilus influenzae. Antimicrob Agents Chemother. 1998;42: 2138-2140.
51. Descheemaeker P, Chapelle S, Lammens C, et al. Macrolide resistance and erythromycin resistance determinants among Belgian Streptococcus pyogenes and Streptococcus pneumoniae isolates. J Antimicrob Chemother. 2000;45:167-173.
52. Pankuch GA, Visalli MA, Jacobs MR, Appelbaum PC. Susceptibilities of penicillin- and erythromycin-susceptible and -resistant pneumococci to HMR 3647 (RU 66647), a new ketolide, compared with susceptibilities to 17 other agents. Antimicrob Agents Chemother. 1998;42:624-630.
53. Felmingham D, Robbins MJ, Leakey A, et al. The comparative in vitro activity of HMR 3647, a ketolide antimicrobial, against clinical bacterial isolates [abstract]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; Toronto, Ontario; September 28-October 1, 1997: 166.
54. Chuah SK, Iskander L, Qazi S, Gollapudi S, Thadepalli H. Experimental Hemophilus influenzae pneumonia: effect of age and telithromycin therapy [abstract]. In: Program and abstracts of the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones; Seville, Spain; January 26-28, 2000. Abstract 3.06.
55. Rajagopalan-Levasseur P, Vallee E, Agouridas C, et al. HMR 3647: activity against erythromycin-resistant pneumococci and Haemophilus influenzae in murine pneumonia models [abstract]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy; Toronto, Ontario; September 28-October 1, 1997:190.
56. Bebear CM, Renaudin H, Bryskier A, Bebear C. Comparative activities of telithromycin (HMR 3647), levofloxacin, and other antimicrobial agents against human mycoplasmas. Antimicrob Agents Chemother. 2000;44:1980-1982.
57. Roblin PM, Hammerschlag MR. In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae. Antimicrob Agents Chemother. 1998;42:1515-1516.
58. Schulin T, Wennersten CB, Ferraro MJ, Moellering RC Jr, Eliopoulos GM. Susceptibilities of Legionella spp. to newer antimicrobials in vitro. Antimicrob Agents Chemother. 1998;42:1520-1523.
59. Namour F, Wessels DH, Pascual MH, Reynolds D, Sultan E, Lenfant B. Pharmacokinetics of the new ketolide telithromycin (HMR 3647) administered in ascending single and multiple doses. Antimicrob Agents Chemother. 2001;45:170-175.
60. Edlund C, Alván G, Barkholt L, Vacheron F, Nord CE. Pharmacokinetics and comparative effects of telithromycin (HMR 3647) and clarithromycin on the oropharyngeal and intestinal microflora. J Antimicrob Chemother. 2000;46:741-749.
61. Drusano G. Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin. Clin Microbiol Infect. 2001;7(suppl 3):24-29.
62. Andrews J, Honeybourne D, Khair O, Jevons G, Vacheron F, Wise R. Penetration of telithromycin (HMR 3647) into bronchial mucosa (BM), epithelial lining fluid (ELF) and alveolar macrophages (AM) following multiple oral doses [abstract]. Available at: www.asmusa .org/memonly/abstracts/AbstractView.asp?AbstractID=33517. Accessibility verified July 17, 2003.
63. Muller-Serieys C, Cantalloube C, Soler P, Gia HP, Brunner F, Lenfant B. Telithromycin (HMR 3647) achieves high and sustained concentrations in bronchopulmonary tissues. In: Program and abstracts of the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones; Seville, Spain; January 26-28, 2000. Abstract 9.26.
64. Gehanno P, Passot V, Nabet P, Sultan E. Telithromycin (HMR 3647) penetrates rapidly into tonsillar tissue achieving high and prolonged tonsillar concentrations [abstract]. Clin Microbiol Infect. 2000;6(suppl 1):204. Abstract MoP251.
65. Gia HP, Roeder V, Namour F, Sultan E, Lenfant B. Telithromycin (HMR 3647) achieves high and sustained concentrations in white blood cells in man. Presented at: 21st International Congress of Chemotherapy; Birmingham, England; July 4-7, 1999.
66. Nicolau DP. Predicting antibacterial response from pharmacodynamic and pharmacokinetic profiles. Infection. 2001;29(suppl 2):11-15.
67. Craig WA, Andes D. Pattern of bactericidal activity with telithromycin against erythromycin-resistant Streptococcus pneumoniae (SP) in the murine thigh-infection model [abstract]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, Ill; September 22-25, 2001:34-35. Abstract A-2098.
68. Sultan E, Namour F, Mauriac C, Lenfant B, Scholtz HE. Telithromycin (HMR 3647), a new ketolide antimicrobial, is metabolised and excreted mainly in faeces in man [abstract]. In: Program and abstracts of the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones; Seville, Spain; January 26-28, 2000. Abstract 9.31.
69. Lenfant B, Perret C, Pascual MH. The bioavailability of HMR 3647, a new once-daily ketolide antimicrobial, is unaffected by food [abstract]. J Antimicrob Chemother. 1999;44(suppl A):55. Abstract P69.
70. Pluim J. Population pharmacokinetics support the convenient once-daily 800 mg dosage of telithromycin in patients with upper and lower RTIs, including special populations [abstract]. Available at: http://congress.akra.ch/abstract/abstract/abt.abs_ausgabe?xssprache= ENG&xsdesign=OPT&xnkon_nr=44&xnpkt_kon_nr=25525. Accessibility verified July 23, 2003.
71. Hagberg L, Torres A, van Rensburg D, Leroy B, Rangaraju M, Ruuth E. Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia. Infection. 2002;30:378-386.
72. Tellier G, Hassman J, Leroy B, Sidarous E, Youngblood D. Oral telithromycin (HMR 3647; 800mg od) is well tolerated and as effective as oral clarithromycin (500mg bid) in community-acquired pneumonia (CAP) in adults [abstract]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; Toronto, Ontario; September 17-20, 2000:471. Abstract 2227.
73. Pullman J, Champlin J, Leroy B, Sidarous E. Oral telithromycin (HMR 3647; 800mg OD) for 7-10 days is well tolerated and as effective as oral trovafloxacin (200mg OD) for 7-10 days in community-acquired pneumonia (CAP) in adults [abstract]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; Toronto, Ontario; September 17-20, 2000:472. Abstract 2230.
74. Van Rensburg DJ, Matthews PA, Leroy B. Efficacy and safety of telithromycin in community-acquired pneumonia. Curr Med Res Opin. 2002;18:397-400.
75. Dunbar L, Hagberg L, Rangaraju M, Leroy B. Seven to 10-day therapy with telithromycin, the first ketolide antimicrobial, is effective in community-acquired pneumonia caused by atypical and intracellular pathogens [abstract]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, Ill; September 22-25, 2001:449. Abstract L-859.
76. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336:243-250.
77. Niki Y, Aoki N, Watanabe A, Kohno S. The efficacy and safety of telithromycin administered once daily at 600 mg or 800 mg in patients with pneumonia [abstract]. In: Program and abstracts of the 12th European Congress of Clinical Microbiology & Infectious Diseases; Milan, Italy; April 24-27, 2002. Abstract P8961.
78. DeAbate CA, Heyder A, Leroy B, Sidarous E, Backstrom J. Oral telithromycin (HMR 3647; 800mg od) for 5 days is well tolerated and as effective as cefuroxime axetil (500mg Bid) for 10 days in adults with acute exacerbations of chronic bronchitis (AECB) [abstract]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; Toronto, Ontario; September 17-20, 2000:471. Abstract 2228.
79. Aubier M, Aldons PM, Leak A, et al. Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis. Respir Med. 2002;96:862-871.
80. Aubier M, Aldons PM, Leak A, et al. Efficacy and tolerability of a 5-day course of a new ketolide antimicrobial, telithromycin (HMR 3647), for the treatment of acute exacerbations of chronic bronchitis (AECB) in patients with COPD [abstract]. Available at: www.asmusa.org/memonly/abstracts/AbstractView.asp?AbstractID=35292. Accessibility verified July 17, 2003.
81. Roos K, Brunswig-Pitschner C, Kostrica R, et al. Efficacy and tolerability of once-daily therapy with telithromycin for 5 or 10 days for the treatment of acute maxillary sinusitis. Chemotherapy. 2002;48:100-108.
82. Tellier G, Lasko B, Leroy B, Sidarous E, Andrade C. Oral telithromycin (HMR 3647; 800mg OD) for 5 days and 10 days is well tolerated and as effective as amoxicillin/clavulanic acid (500/125mg TID) for 10 days in acute maxillary sinusitis (AMS) in adults [abstract]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; Toronto, Ontario; September 17-20, 2000:471. Abstract 2226.
83. Buchanan P, McNeil D, Tady D, Andrade C, Leroy B. A 5-day course of telithromycin, the first ketolide antibacterial, is as effective as 10 days' cefuroxime axetil in the treatment of acute maxillary sinusitis [abstract]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago, Ill; September 22-25, 2001:461. Abstract L-910.
84. Aventis Pharma. Data on file: integrated summary of safety information (8:v251). Aventis Pharma; 2003:159-160-168-180.
85. Rangaraju M, Leroy B, Pluim J. Telithromycin is highly effective in the treatment of community-acquired respiratory tract infections caused by resistant pneumococci [abstract]. In: Program and abstracts of the 6th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones; Bologna, Italy; January 23-26, 2002. Abstract 8.03.
86. Labbe G, Flor M, Lenfant B. Cytochrome P450 (CYP-450) activity is not inhibited in vitro by telithromycin (HMR 3647), a new ketolide antimicrobial [abstract]. In: Program and abstracts of the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones; Seville, Spain; January 26-28, 2000. Abstract 9.28.
87. Scholtz HE, Sultan E, Wessels D, Hundt AF, Passot V, Vacheron F. Telithromycin (HMR 3647), a new ketolide antimicrobial, does not affect the reliability of low-dose, triphasic oral contraceptives [abstract]. In: Program and abstracts of the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones; Seville, Spain; January 26-28, 2000. Abstract 9.29.
88. Scholtz HE, Pretorius SG, Wessels DH, Mogilnicka EM, van Niekerk N, Sultan E. Telithromycin (HMR 3647), a new ketolide antimicrobial, does not affect the pharmacodynamics or pharmacokinetics of warfarin [abstract]. In: Program and abstracts of the 5th International Conference on the Macrolides, Azalides, Streptogramins, Ketolides and Oxazolidinones; Seville, Spain; January 26-28, 2000. Abstract 9.30.
89. Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents: drug interactions of clinical significance. Drug Saf. 1998; 18:83-97.
90. Barman Balfour JA, Figgitt DP. Telithromycin. Drugs. 2001;61: 815-829.
91. Demolis JL, Vacheron F, Cardus S, Funck-Brentano C. Effect of single and repeated oral doses of telithromycin on cardiac QT interval in healthy subjects. Clin Pharmacol Ther. 2003;73:242-252.